Published in Curr Opin Endocrinol Diabetes Obes on August 01, 2014
Proteomic Analysis of Disease Stratified Human Pancreas Tissue Indicates Unique Signature of Type 1 Diabetes. PLoS One (2015) 0.80
Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes. Front Immunol (2016) 0.78
Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets. F1000Res (2016) 0.77
Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes. Stem Cells (2016) 0.76
Implication of the intestinal microbiome as a potential surrogate marker of immune responsiveness to experimental therapies in autoimmune diabetes. PLoS One (2017) 0.75
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A (2007) 6.44
Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet (1974) 5.59
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011) 4.30
Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes (1996) 4.20
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A (2000) 3.89
Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol (1988) 3.43
Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest (2004) 3.17
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med (2012) 2.86
Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes (2004) 2.74
Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes (2010) 2.36
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol (2013) 2.23
Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab (2004) 2.19
Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest (2006) 2.08
11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med (2009) 1.99
Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest (2010) 1.93
Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol (2010) 1.82
Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A (2011) 1.77
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med (2010) 1.61
Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab (2003) 1.55
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49
Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes (2009) 1.43
Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes (2004) 1.39
Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes (1999) 1.38
Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. Diabetes (2011) 1.33
Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia (2012) 1.29
Rituximab selectively suppresses specific islet antibodies. Diabetes (2011) 1.23
Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol (2010) 1.22
Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol (2011) 1.20
Circulating miR-375 as a biomarker of β-cell death and diabetes in mice. Endocrinology (2013) 1.14
GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes (2000) 1.10
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med (2012) 1.10
Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice. PLoS One (2012) 1.07
VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease. Diabetes Obes Metab (2008) 0.97
Insulin and islet cell autoantibodies as time-dependent covariates in the development of insulin-dependent diabetes: a prospective study in relatives. J Clin Endocrinol Metab (1993) 0.85
A humanized mouse model of autoimmune insulitis. Diabetes (2014) 0.85
Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial. Diabetes Care (2013) 0.78
Large-scale prospective T cell function assays in shipped, unfrozen blood samples: experiences from the multicenter TRIGR trial. Clin Vaccine Immunol (2013) 0.78
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Insulin secretion in type 1 diabetes. Diabetes (2004) 2.59
Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes (2006) 2.52
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology (2007) 2.33
A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol (2007) 2.23
Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2006) 2.15
Natural history of beta-cell function in type 1 diabetes. Diabetes (2005) 1.98
Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity (2010) 1.98
Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care (2007) 1.87
Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A (2011) 1.77
Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest (2013) 1.76
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74
Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes (2008) 1.69
Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol (2004) 1.55
Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol (2009) 1.53
Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes (2011) 1.52
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes (2006) 1.49
Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells. J Clin Invest (2015) 1.43
RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol (2008) 1.41
Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol (2011) 1.39
Immune therapy and β-cell death in type 1 diabetes. Diabetes (2013) 1.33
β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest (2015) 1.31
Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol (2010) 1.22
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nat Rev Drug Discov (2011) 1.21
Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab (2008) 1.21
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes (2013) 1.19
Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med (2012) 1.10
RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS One (2012) 1.09
Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol (2005) 1.09
Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough. Ann N Y Acad Sci (2007) 1.08
Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol (2010) 1.06
In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med (2012) 1.01
The role of AIRE in human autoimmune disease. Nat Rev Endocrinol (2010) 1.00
Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose. Diabetes (2011) 0.98
Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev (2009) 0.95
Analysis of β-cell death in type 1 diabetes by droplet digital PCR. Endocrinology (2014) 0.93
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes (2013) 0.93
A carbon nanotube-polymer composite for T-cell therapy. Nat Nanotechnol (2014) 0.93
Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol (2013) 0.92
RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restor Neurol Neurosci (2005) 0.90
A patient with type B insulin resistance syndrome, responsive to immune therapy. Nat Clin Pract Endocrinol Metab (2007) 0.89
The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes (2012) 0.88
Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage. Endocrinol Metab Clin North Am (2009) 0.88
Rituximab does not reset defective early B cell tolerance checkpoints. J Clin Invest (2015) 0.87
Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care (2014) 0.86
Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 0.85
Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors. Endocrinology (2009) 0.85
A humanized mouse model of autoimmune insulitis. Diabetes (2014) 0.85
NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody. Eur J Immunol (2011) 0.85
Human regulatory CD8 T cells. Ann N Y Acad Sci (2008) 0.85
New and future immunomodulatory therapy in type 1 diabetes. Trends Mol Med (2012) 0.83
Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care (2013) 0.83
Promotion of beta-cell differentiation in pancreatic precursor cells by adult islet cells. Endocrinology (2008) 0.83
Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes. Ann N Y Acad Sci (2004) 0.82
Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala). Hum Immunol (2008) 0.81
Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opin Biol Ther (2014) 0.81
Drug insight: New immunomodulatory therapies in type 1 diabetes. Nat Clin Pract Endocrinol Metab (2006) 0.81
Characterization of residual β cell function in long-standing type 1 diabetes. Diabetes Metab Res Rev (2014) 0.81
Regulatory T cells and type 1 diabetes. Curr Diab Rep (2005) 0.81
Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation. Curr Diab Rep (2004) 0.81
Receptor for advanced glycation end products and its ligands: initiators or amplifiers of joint inflammation--a bit of both? Arthritis Rheum (2006) 0.80
Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass. Novartis Found Symp (2008) 0.79
Islet transplantation for type 1 diabetes--where should we go? Nat Clin Pract Endocrinol Metab (2007) 0.79
Delayed anti-CD3 therapy in a mouse heart transplant model induced tolerance and long-term survival of allograft: achieving tolerance. Immunotherapy (2013) 0.78
Functional human to mouse adipose tissue xenotransplantation. J Endocrinol (2011) 0.78
Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals. J Acquir Immune Defic Syndr (2016) 0.78
Treatment of type 1 diabetes with anti-CD3 monoclonal antibody. Rev Endocr Metab Disord (2003) 0.77
Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev (2009) 0.76
Pancreatic islets activate portal vein endothelial cells in vitro. Ann Clin Lab Sci (2002) 0.76
Continuous glucose monitoring: long live the revolution! Nat Clin Pract Endocrinol Metab (2008) 0.76
Prevention of T1DM: feeding the ultimate goal. Nat Rev Endocrinol (2011) 0.75
Novel SIRT1 mutation linked to autoimmune diabetes in humans. Cell Metab (2013) 0.75
Continuous subcutaneous insulin infusion in older patients with type 1 diabetes. Diabetes Care (2004) 0.75